Markets:

Overview

News

Currencies

International

Treasuries

Merck & Co (NY:MRK)

92.93 UNCHANGED

Streaming Delayed Price Updated: 7:00 PM EST, Nov 13, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Merck & Co

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Nanomedicine Innovations Transforming Oncology Drug Delivery and Bioavailability

October 29, 2025

Via Investor Brand Network

Merck and Eisai Provide Update on Phase 3 LEAP-012 Trial in Unresectable, Non-Metastatic Hepatocellular Carcinoma

October 29, 2025

From Merck & Co., Inc.

Via Business Wire

European Commission Approves KEYTRUDA® (pembrolizumab) as Part of a Treatment Regimen for Adults with Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma (LA-HNSCC) Expressing PD-L1 (CPS >1)

October 29, 2025

From Merck & Co., Inc.

Via Business Wire

Merck & Co Unusual Options Activity ↗

October 22, 2025

Via Benzinga

Nanomedicine Innovations Transforming Oncology Drug Delivery and Bioavailability

October 29, 2025

EQNX::TICKER_START (OTCQB:OTLC),(NASDAQ:IOVA),(NYSE:MRK),(NYSE:LLY),(NYSE:JNJ) EQNX::TICKER_END

Via FinancialNewsMedia

Merck (MRK) Reports Earnings Tomorrow: What To Expect

October 28, 2025

Global pharmaceutical company Merck (NYSE:MRK) will be reporting earnings this Thursday morning. Here’s what you need to know.

Via StockStory

Topics Artificial Intelligence

Looking At Merck & Co's Recent Unusual Options Activity ↗

October 28, 2025

Via Benzinga

Merck's New Cancer Therapy Combo Shows Significant Edge Over Rivals In Renal Cancer ↗

October 28, 2025

Merck and Eisai report Phase 3 results showing Welireg plus Lenvima significantly improved progression-free survival in advanced kidney cancer.

Via Benzinga

Merck Announces KEYTRUDA® (pembrolizumab) Plus WELIREG® (belzutifan) Met Primary Endpoint of Disease-Free Survival (DFS) in Certain Patients With Clear Cell Renal Cell Carcinoma (RCC) Following Nephrectomy

October 28, 2025

From Merck & Co., Inc.

Via Business Wire

Merck and Eisai Announce WELIREG® (belzutifan) Plus LENVIMA® (lenvatinib) Met Primary Endpoint of Progression-Free Survival (PFS) in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma

October 28, 2025

From Merck & Co., Inc.

Via Business Wire

Healthcare Sector Navigates Volatile Waters as S&P 500 Closes: A Deep Dive into Key Market Drivers

October 27, 2025

As the closing bell rings on October 27, 2025, the S&P 500 Healthcare sector stands at a critical juncture, exhibiting the nuanced volatility that defines this essential yet complex segment of the...

Via MarketMinute

Topics Artificial Intelligence Economy Intellectual Property

3 Dividend-Paying Drug Stocks to Buy at a Discount ↗

October 27, 2025

Some of the largest drugmakers in the world are trading at attractive valuations. Are they worth buying?

Via The Motley Fool

Topics Intellectual Property

How Is The Market Feeling About Merck & Co Inc? ↗

October 27, 2025

Via Benzinga

3 Healthcare Stocks to Buy Hand Over Fist in October ↗

October 27, 2025

One growth stock, one high-yield stock, and one Dividend King -- you should find something you like here as October draws to a close.

Via The Motley Fool

Topics Intellectual Property

U.S. FDA Approves Updated Indication for WINREVAIR™ (sotatercept-csrk) in Adults with Pulmonary Arterial Hypertension (PAH, WHO* Group 1 Pulmonary Hypertension) Based on Phase 3 ZENITH Study

October 27, 2025

From Merck & Co., Inc.

Via Business Wire

3 Healthcare Stocks That Are Screaming Deals Right Now ↗

October 26, 2025

These bargains could prove good for your financial health.

Via The Motley Fool

Topics Intellectual Property

Flash PMI: The Early Warning System Guiding the Federal Reserve's Hand

October 23, 2025

Flash Purchasing Managers' Index (PMI) data, a critical economic bellwether, continues to command significant attention from financial markets and policymakers alike. Released typically a week or two...

Via MarketMinute

Topics Bonds Economy Supply Chain

ONEOK’s 6% Dividend Draws Smart Money Despite a Nearly 30% Drop ↗

October 23, 2025

ONEOK’s 6% Dividend Draws Smart Money Despite a Nearly 30% Drop

Via The Motley Fool

Topics Energy Regulatory Compliance

Why Some Investors Are Taking Profits on JPMorgan After Its Big Rally ↗

October 23, 2025

Why Some Investors Are Taking Profits on JPMorgan After Its Big Rally

Via The Motley Fool

Merck to Present New Data from Its Innovative Cardio-Pulmonary Pipeline and Portfolio at AHA Scientific Sessions 2025

October 23, 2025

From Merck & Co., Inc.

Via Business Wire

FDA Grants Priority Review for KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each in Combination with Padcev® (enfortumab vedotin-ejfv), for Certain Patients with Muscle-Invasive Bladder Cancer

October 23, 2025

From Merck & Co.

Via Business Wire

AI Revolutionizes Drug Discovery and Personalized Medicine: A New Era of Healthcare

October 22, 2025

The pharmaceutical and biotechnology industries are undergoing a profound transformation, driven by an urgent need for more efficient drug discovery and development processes and the paradigm shift...

Via TokenRing AI

Topics Animal Testing Artificial Intelligence

Systematic Review of 15 Studies Focused on Epidemiology and Antimicrobial Resistance of Pneumococcal Serotypes Covered by CAPVAXIVE® (Pneumococcal 21-valent Conjugate Vaccine) in U.S. Adults

October 21, 2025

From Merck & Co., Inc.

Via Business Wire

What's Going On With Summit Therapeutics Stock On Monday? ↗

October 20, 2025

Summit Therapeutics shares Phase 3 data showing ivonescimab cut cancer progression risk by 40% and plans BLA submission in late 2025.

Via Benzinga

2 Beaten-Down Stocks to Buy and Hold for the Next Decade ↗

October 20, 2025

That's plenty of time for these drugmakers to move past their challenges.

Via The Motley Fool

KEYTRUDA® (pembrolizumab) Demonstrates Long-Term Survival Benefit in Certain Patients With Earlier or Advanced Stages of Non-Small Cell Lung Cancer (NSCLC)

October 20, 2025

From Merck & Co., Inc.

Via Business Wire

Market Minute: Dow Soars, Apple Hits Record High as 20-Day Government Shutdown Fuels Gold Rally

October 20, 2025

The U.S. financial markets opened the week with a robust performance on October 20, 2025, as the Dow Jones Industrial Average (DJIA) extended its gains, and tech giant Apple Inc. (NASDAQ: AAPL) reached...

Via MarketMinute

Topics Artificial Intelligence Economy Stocks

Merck Breaks Ground on $3 Billion Center of Excellence for Pharmaceutical Manufacturing in Elkton, Virginia

October 20, 2025

From Merck & Co., Inc.

Via Business Wire

Biotech Boom: Strategic Realignments and AI Integration Fuel Investor Focus, Signaling Broader Market Shifts

October 19, 2025

The biotechnology sector is currently experiencing a significant surge in investor attention, characterized by a blend of cautious optimism and strategic focus. As of October 2025, this heightened...

Via MarketMinute

Topics Artificial Intelligence ETFs Economy

Raludotatug Deruxtecan Demonstrated Clinically Meaningful Response Rates in Patients with Recurrent Platinum-Resistant Ovarian, Primary Peritoneal or Fallopian Tube Cancer in Phase 2 Part of REJOICE-Ovarian01 Phase 2/3 Trial

October 19, 2025

From Daiichi Sankyo

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Merck & Co (NY:MRK)

All News about Merck & Co

Starting at $3.75/week.

Subscribe Today